Brought to you by 
Terns Pharmaceuticals launched with $30mm Series A from Lilly Asia
06 Apr 2018
Executive Summary
Terns Pharmaceuticals Inc. raised $30mm in Series A funding from Lilly Asia Ventures. The company was recently launched and is developing molecularly-targeted oral small-molecule candidates for liver diseases (including nonalcoholic steatohepatitis) and cancer. Terns is based in California and Shanghai, and intends to initially focus its drug development efforts on unmet medical needs in China.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Terns Pharmaceuticals launched with $30mm Series A from Lilly Asia
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice